Bill Tiller joins Greenwood Genetic Center Foundation see more
The Greenwood Genetic Center (GGC) has named William ‘Bill’ Tiller as the new Executive Director of the GGC Foundation.
Tiller comes to GGC with a long and successful career in fundraising and development, working primarily in the areas of children’s health and advocacy. He has secured and directed approximately $43 million to support numerous nonprofit organizations including The Meyer Center for Special Children, Make-A-Wish Foundation of SC, and most recently served as President and CEO of the Pediatric Brain Tumor Foundation.
"We are thrilled to have someone with Bill's experience and passion for serving families who are affected by birth defects, disabilities, and autism," said Boo Ramage, outgoing Interim Executive Director of the GGC Foundation. Ramage stepped in to temporarily lead the 501(c)3 fundraising arm of GGC last July, successfully steering the final phase of the $1.56 million ‘Journey of Discovery’ campaign that supported several innovative technologies in research and diagnostic testing.
“GGC has been so fortunate to have strong philanthropic support throughout our history,” said Steve Skinner, MD, Director of GGC. “Bill brings valuable expertise as we expand our reach and advance our mission to serve families with compassion and expertise.”
“I feel a deep sense of calling to the mission of GGC, and I pledge to move the mission forward with purpose and joy," said Tiller. "I look forward to working alongside GGC’s distinguished professionals, in partnership with donors and investors, and in service to the many children and families who look to GGC for comfort and care."
To learn more about Tiller and the GGC Foundation, visit www.GGC.org/foundation.
Major grant awarded to Greenwood Genetic Center see more
The National MPS Society has awarded a $100,000 grant to the Greenwood Genetic Center (GGC). Richard Steet, PhD, Director of Research at GGC, is the lead investigator on the two-year project aimed at improving the diagnosis and hastening treatment for patients with these rare disorders.
Mucopolysaccharidoses (MPS) and related disorders, as a group, affect approximately 1 in 25,000 individuals. The MPS Society provides support resources for families as well as funding for research into this group of disorders which can affect the health, development, quality of life and lifespan of affected individuals. GGC has a long-standing interest in MPS disorders including providing clinical care, diagnostic testing, and research for many of these rare conditions.
Several of these conditions have been added to newborn screening, also known as the heel prick test, that screens all infants at birth for a variety of treatable genetic disorders. The Biochemical Diagnostic Laboratory at GGC is directly involved with secondary testing of newborns that receive a positive screening result.
According to Steet, these newborn screening efforts are identifying new changes within genes related to MPS disorders that aren’t always easily interpreted, leading to uncertainty in the diagnosis.
“Some of these novel changes may be disease-causing, while others are not,” said Steet. “Not knowing the significance of the gene changes puts patients and families in a state of limbo, uncertain as to whether they should start therapy.”
As more states, including South Carolina, are starting to screen for MPS disorders at birth, Steet and his colleagues in the Research and Diagnostic Divisions at GGC are developing cell- and zebrafish-based models to determine which of these gene changes are false positives and which are true mutations.
“Once the significance of these changes is known, then labs around the world who are running these tests can report their results with confidence, families with false positives can be reassured, and those with true mutations can start life-altering treatment without further delay,” said Steet.
“The National MPS Society is honored to support Dr. Steet’s research in the development of newborn screening assays,” said Terri Klein, President and CEO of the National MPS Society. “GGC produces groundbreaking research that is key to unlocking the understanding of these rare diseases. MPS is a life-limiting disease, and children lose their battle early. Moving science forward will help change the outcomes of children diagnosed now and in the future.”
About Greenwood Genetic Center
The Greenwood Genetic Center (GGC), founded in 1974, is a nonprofit organization advancing the field of medical genetics and caring for families impacted by genetic disease and birth defects. At its home campus in Greenwood, South Carolina, a talented team of physicians and scientists provides clinical genetic services, diagnostic laboratory testing, educational programs and resources, and research in the field of medical genetics. GGC’s faculty and staff are committed to the goal of developing preventive and curative therapies for the individuals and families they serve. GGC extends its reach as a resource to all residents of South Carolina with satellite offices in Charleston, Columbia, Florence, and Greenville. The GGC Foundation provides philanthropic financial support for the mission of the Center. For more information about GGC or the GGC Foundation please visit www.ggc.org.
About the MPS Society
The National MPS Society exists to cure, support, and advocate for MPS and ML. Their mission serves individuals, families, and friends affected by Mucopolysaccharidoses and Mucolipidosis through supporting research, supporting families, and increasing public and professional awareness. For more information on MPS and ML, please visit www.mpssociety.org.
GGC Partnership Campus website to market for future growth see more
Courtesy of GSA Biz Wire
The Greenwood Genetic Center (GGC) Foundation, a nonprofit 501c3 established to serve as the philanthropic arm supporting the mission of the Greenwood Genetic Center, is proud to announce the launch of a new website highlighting their GGC Partnership Campus at http://partnershipcampus.com/.
The GGC Partnership Campus will serve as both an anchor of Greenwood’s emerging Medical Innovation District and as a vital, connected hub within the broader Greenwood community. The campus will become the location of choice for companies and organizations seeking a quality-of-life environment with a focus on promoting connections and collaboration.
The GGC Partnership Campus will provide a unique asset for the City of Greenwood while supporting GGC’s long-term goals for the delivery of clinical care, diagnostic testing, research advances, and educational initiatives.
In addition to the Greenwood Genetic Center, the campus currently includes The Upper Savannah Council of Governments, Carolina Health Center’s Children's Center, and the Clemson Center for Human Genetics’ Self Regional Hall.
The Clemson Center for Human Genetics’ (CCHG) presence on the campus enables Clemson’s growing genetics program to collaborate closely with the tradition of excellence in genetic services, testing, and research at GGC, combining basic science with clinical care. Last year, CCHG named internationally acclaimed geneticist, Dr. Trudy Mackay, as Director of CCHG. Dr. Mackay is building a team of researchers to advance the understanding of the fundamental principles by which genetic and environmental factors determine and predict both healthy traits and susceptibility to disease in humans. Together, the CCHG and GGC will strive to use new technologies and knowledge to develop treatments for genetic disorders.
The GGC Partnership Campus website features a streamlined modern design, improved functionality, and easy access to essential information to help individuals and companies looking to locate on the GGC Partnership Campus. The new comprehensive website offers campus information, relocation assistance, a facilities overview, news, and contact information.
About The Greenwood Genetic Center Foundation
The GGC Foundation is a nonprofit 501c3 established to serve as the philanthropic arm supporting the Greenwood Genetic Center (GGC) in their work of serving families in the fight against genetic diseases, birth defects and autism. GGC has provided over 45 years of compassionate clinical care, unparalleled diagnostic lab services, globally-renowned research discoveries, and innovative educational programs. Visit ggc.org/foundation.
Greenwood Genetic Center, MUSC affiliate to improve patient access to innovations in genetic servicesMUSC partners with Greenwood Genetic Center see more
The Greenwood Genetic Center (GGC) and the Medical University of South Carolina (MUSC) have signed an affiliation agreement with the goal of providing patients across South Carolina with accessible, high-quality, coordinated and cost-effective genetic services through a collaborative approach to providing medical care. The two entities have worked together informally on clinical consultations, provider education and research for more than a decade. This affiliation seeks to formalize and expand the depth and breadth of the relationship. According to MUSC, a partnership with the state’s most advanced and innovative genetic center was an easy choice.
“I live in Greenwood, and I’ve said for years that a lot people don’t understand what an absolute gem this center is,” said Charles Schulze, chairman of the MUSC Board of Trustees. “They’ve helped almost 100,000 families across the state make incredibly important decisions, unmasked difficult-to-diagnose conditions, and have been there for these families every step of the way when faced with good news, or not so good news.”
While there are any number of reasons people may want to learn more about how their genetics may affect their or their loved ones health, all patients want the same thing: high-quality care at the lowest cost and access to the latest technologies, diagnostics and research related to their genetic stories. In the interest of better serving these needs, the initial goals of the partnership include:
- Increasing access to clinical genetic services for MUSC patients and all South Carolinians
- Optimizing the patient journey to improve wait times for appointments and consultations
- Sharing critical resources and expertise where possible to lower costs
- Pursuing workforce development, research, clinical trials and treatment collaborations.
Nearly every child in South Carolina who was diagnosed with a genetic birth defect, developmental delay or other hereditary disorder has already been referred to GGC, due to the center’s expertise with rare conditions and commitment to new technologies and diagnostics. GGC, a nonprofit institute centered on research, clinical genetic services, diagnostic laboratory testing and educational programs and resources, is focused on compassionate patient care and innovative scientific advancement.
About Greenwood Genetic Center
The Greenwood Genetic Center (GGC), founded in 1974, is a nonprofit organization advancing the field of medical genetics and caring for families impacted by genetic disease and birth defects. At its home campus in Greenwood, South Carolina, a talented team of physicians and scientists provides clinical genetic services, diagnostic laboratory testing, educational programs and resources, and research in the field of medical genetics. GGC’s faculty and staff are committed to the goal of developing preventive and curative therapies for the individuals and families they serve. GGC extends its reach as a resource to all residents of South Carolina with satellite offices in Charleston, Columbia, Florence and Greenville. For more information about GGC please visit www.ggc.org.
Greenwood, SC is an emerging player in life sciences... see more
As far as Sam Konduros, President and CEO of SCBIO, is concerned, the Palmetto State boasts a surprise player among the major hubs for cutting edge biotech study.
“When I talk about the four major research institutions in the state of South Carolina, it’s our three research universities and Greenwood Genetic (Center), that’s how good that team is,” Konduros, CEO of SCBIO, told the Greenwood Partnership Alliance’s board this week. “People don’t know South Carolina as a life sciences story, they don’t know Greenwood, so we’re really surprising our own population with what we do have, and then we’re spending a lot of time trying to make sure that message is getting out around the world.”
Greenwood County is one of South Carolina's hidden gems when it comes to life sciences see more
This month, Greenville Business Magazine travels to see the incredible life sciences success stories emerging from nearby Greenwood, S.C.
As demand for health care grows and medical advances stretch from research to manufacturing, life sciences has become an inviting target industry for economic developers seeking to attract jobs and investment. While some communities are learning as they go, Greenwood County has in one way or another made life sciences a priority for decades. It’s paying off in high-tech jobs and multi-million-dollar investments. Read on for the complete story...
The Greenwood Genetic Center has named Richard Steet, PhD as Director of Research see more
GREENWOOD, South Carolina – The Greenwood Genetic Center has named Richard Steet, PhD as Director of Research and Head of the JC Self Research Institute. He joins the GGC faculty from the University of Georgia where he was Professor of Biochemistry and Molecular Biology in the University’s Complex Carbohydrate Research Center.
Steet’s research program, which is funded by the NIH and private foundations, is focused on defining disease mechanisms for two different classes of inherited diseases - lysosomal storage disorders and congenital disorders of glycosylation. Dr. Steet is also a dedicated advocate of rare disease research and serves on the scientific advisory boards for the National MPS Society and ISMRD, two organizations that provide family support and advance research.
“I am thrilled to become part of the world-renowned Greenwood Genetic Center, and I look forward to collaborating with their clinical and diagnostic divisions to enhance our understanding of the genetic basis for birth defects and disabilities,” said Steet.
Steet’s additional goals for the Center’s Research Division include integrating the Center’s strengths in basic science research with clinical and translational studies. He also plans to enhance partnerships with pharmaceutical companies that can drive therapeutic development for genetic disorders.
Steet and Heather Flanagan-Steet, PhD, who also joins GGC’s faculty as Director of Functional Studies and Director of the Center’s new Aquaculture Facility, study both cell and animal-based models of human disease. Their work uses a combination of chemical, molecular, and developmental approaches to unravel the complexity of these disorders and explore new ways to treat them. Their efforts will dovetail in many ways with the mission of the Clemson Center for Human Genetics, located adjacent to the JC Self Research Institute.
The Steets have been working with GGC over the past several months to set up a new aquaculture facility at the Center that, once fully operational, will house over 10,000 zebrafish. The facility, along with a new confocal microscope, which will arrive at GGC this fall, will allow in depth characterization of zebrafish models for several human genetic diseases. Their zebrafish and cell models will be further leveraged to study challenging cases seen in the clinic and diagnostic labs.
“Zebrafish, who share approximately 70% of their genes with humans, are a powerful model organism for genetic disorders,” shared Flanagan-Steet. “Since zebrafish embryos are clear, we can observe their development from the very beginning and learn how genetic factors lead to the disease-associated features that we see in patients.”
“GGC is fortunate to have the expertise of both Dr. Steet and Dr. Flanagan-Steet, and we are excited as our research program expands to include our first animal model,” said Steve Skinner, MD, Director of GGC. “The potential of this new area of study is tremendous, and what we learn through their lab will undoubtedly move us closer to developing effective treatments for patients with rare genetic disorders.”
Steet assumes the directorship from Charles Schwartz, PhD who joined GGC in 1985 as the Director of the Center’s Molecular Laboratory, and shifted his focus to lead research initiatives in 1996. Schwartz earned an international reputation in the area of X-linked intellectual disability. He remains on GGC faculty as a Senior Research Scientist.
State-of-the-art facility equipped with world-class labs, technologically advanced instrumentation see more
The Clemson Center for Human Genetics officially opened for business Tuesday evening, celebrating with an enthusiastic gathering of supporters who met with scientists and toured the state-of-the-art facility.
Piloted by a cadre of researchers equipped with world-class laboratories and technologically advanced instrumentation, Clemson’s Center for Human Genetics has successfully landed on the global stage – both in talent and scope. The center, which is part of Clemson’s College of Science, is dedicated to advancing knowledge of the fundamental principles by which genetic and environmental factors determine and predict healthy traits and susceptibility to disease.
The center is housed in Self Regional Hall with eight laboratories and several classrooms, conference rooms and offices for faculty and graduate students. The 17,000-square-foot building is located on the campus of the Greenwood Genetic Center. During Tuesday’s event, the labs and hallways were jammed with guests.
Trudy Mackay, director of the Center for Human Genetics, is recognized as one of the world’s leading authorities on the genetics of complex traits. Mackay, the Self Family Endowed Chair in Human Genetics and Professor of Genetics and Biochemistry, is a fellow of the American Association for the Advancement of Science. She has also been elected to the American Academy of Arts and Sciences, the Royal Society of London and the National Academy of Sciences.
Mackay is joined at Clemson by Robert Anholt, Provost’s Distinguished Professor of Genetics and Biochemistry and director of Faculty Excellence Initiatives in the College of Science. Anholt is also a member of the American Association for the Advancement of Science.
“This is an exciting time in the field of human genetics and its connection to health and well-being,” said Mackay, who has won numerous international awards, including the prestigious Wolf Prize, published more than 200 papers and trained graduate and postdoctoral students who have gone on to represent the next generation of geneticists. “We now know that all of us are 99.9 percent identical in our DNA, but that 10th of a percent difference translates to 3 million small genetic differences between any two of us. The challenge now is to understand how these molecular differences in DNA affect our susceptibility to diseases like cancer and heart ailments.”
Tuesday’s event was the culmination of 13 years of planning, collaboration and diligence. The naming of Self Regional Hall recognized the ongoing support from Self Regional Healthcare, which has contributed $5.6 million to the facility. In addition, the $4 million endowed chair held by Mackay was funded equally by the Self Family Foundation and the state of South Carolina.
“We are confident that our investment in the Self Family Endowed Chair for Human Genetics will pay huge dividends in furthering research to prevent, treat and cure genetic disorders,” said Frank Wideman, president of the Self Family Foundation. “We believe the synergy brought about by the intellectual capital of the Clemson Center for Human Genetics and that of the Greenwood Genetic Center has unlimited potential.”
Clemson University President James P. Clements praised the Self family, the city of Greenwood, Greenwood County, the Greenwood Commissioners of Public Works and the Greenwood Partnership Alliance for their generous support.
“Our partnership with the Greenwood Genetic Center, along with the amazing support we are receiving from Self Regional Healthcare and the Self Family Foundation, will allow our faculty researchers to translate their findings into tangible treatment options more quickly and efficiently,” Clements said. “The work being done here has the potential to make a huge difference in improving lives, which is at the core of Clemson’s mission as a land-grant university.”
Mackay and Anholt came to Clemson from North Carolina State, where they had conducted research for a combined 55 years. Most of Mackay’s new Clemson team also hail from N.C. State, including staff scientists Richard Lyman and Roberta Lyman, postdoctoral research associate Chad Highfill and doctoral students Brandon Baker and Sneha Mokashi. Rebecca Jones, who graduated with a bachelor’s degree in genetics from Clemson in May 2018, will be joining the team as a graduate student. Karl Kelly will continue to provide support as director of operations.
The Center for Human Genetics will work in partnership with the Greenwood Genetic Center, a nonprofit institute that focuses on clinical genetic services, diagnostic laboratory testing, educational programs and research. Mackay and her team will interact regularly with Greenwood Genetic Center personnel.
“This is an outstanding example of how the power of partnership can collectively harness talent to improve lives,” said Cynthia Y. Young, founding dean of Clemson’s College of Science. “Together, we have put a stake in the ground to develop a globally recognized center of excellence around human genetics anchored by some of the world’s most talented scientists.”
Dr. Steve Skinner, director of the Greenwood Genetic Center, said that the impact of the collaboration between the two centers will be transformative for genomics medicine.
“With the research expertise of Drs. Mackay and Anholt, and GGC’s illustrious history of providing clinical care and human genetics advancements, our combined efforts will advance the understanding of human diseases and behaviors, as well as guide us toward potential treatments to improve the quality of life for those impacted by neurodevelopmental and other genetic disorders.”
Skinner cited the recent joint acquisition of a NovaSeq 6000 DNA sequencer from Illumina as proof of the potency of the partnership.
“The NovaSeq is the most powerful sequencer available, and we have the only one in South Carolina,” Skinner said. “This instrument not only increases our DNA sequencing capacity and ability to diagnose complex patients though whole genome sequencing, it also provides genomic data to advance Clemson’s studies and GGC’s zebrafish models with the ultimate goal of improving patient health and quality of life.”
The main goals of the Center for Human Genetics include:
Leverage comprehensive genetic approaches and comparative genomics to explain the fundamental principles of human complex traits, including disease risk.
Promote precision medicine.
Develop local, regional, national and international collaborations to advance human genetics.
Educate the next generation of human geneticists.
Promote public understanding of human genetics through community outreach.
Much of the above will be accomplished by studying the inner workings of an insect that is smaller than a grain of rice. The fruit fly Drosophila melanogaster has turned out to be a remarkably powerful gene discovery system for large-scale, population-based genetic studies. About 70 percent of fly genes have human counterparts, which enable the construction of contextual genetic networks. Using the fly as their catalyst, Mackay and her team will seek new breakthroughs in the treatment of addiction, glaucoma, alcohol and fatty liver disease, oxidative stress, heavy metal toxicity, aging and neurological disorders.
“I am proud to lead Clemson’s Center for Human Genetics in Greenwood,” Mackay said. “We will have a strong connection to the main campus at Clemson to strengthen our research and academic core. Together with our partners, we will accomplish a great deal in the coming years.”
Personalized approaches to treating autism spectrum disorder advance... see more
The Greenwood Genetic Center and Swiss biotechnology innovator, Stalicla, have signed a research agreement to collaborate on personalized approaches to treating autism spectrum disorder, or ASD. Stalicla has developed an algorithm platform based on big data to bring precision medicine to subtypes of autism spectrum disorder patients, according to a news release.
“Over the past 10 years, evidence has accumulated pointing toward alterations in molecular pathways that lead to abnormal cell functioning in ASD,” said Lynn Durham, CEO of Geneva-based Stalicla, in the release. “At Stalicla, we are looking to bring disease-modifying personalized medicine to patients with ASD, one subgroup after the other.”
Greenwood Genetic Center has set its sights on growing see more
The Greenwood Genetic Center has partnered with Greenwood County, South Carolina’s economic development arm on a plan to add new investors to its campus. Read on for full details...